Emalex Biosciences
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Founded in 1/1/18
Chicago, Illinois, United States
For Profit
About Emalex Biosciences
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders. The company's first development candidate Ecopipam, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. Emalex Biosciences was founded in 2018 by Jeff Aronin.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue: Less than $1M
- Total Funding: 300000000 USD
- Last Funding: 250000000 USD (Series D)
- Funding Status: Late Stage Venture
Technology Stack
Emalex Biosciences actively uses None products in their tech stack.
Market Presence
Industries: Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Headquarters: Chicago, Illinois, United States